Vertex CEO to UK Prime Minister: You’re devaluing lives, passing up a great offer and threatening the country’s biotech industry
Vertex has scored big in the US with its new drugs for cystic fibrosis, but the biotech still has to slug it out for every inch of market territory in Europe — where its price for Orkambi is often seen as way too high for the value it offers. And after getting snubbed in the UK last week — again — after a long-running campaign to win a reimbursement deal from the NHS, CEO Jeffrey Leiden has decided to publicly chastise British Prime Minister Theresa May for the standoff.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.